Loading...
•
Jun 30, 2023
TherapeuticsMD Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023.
Key Takeaways
TherapeuticsMD reported a net loss from continuing operations of $2.4 million for the second quarter of 2023, with license and service revenues of $0.4 million. The company is transitioning to a royalty-based business and focusing on cost reduction.
Net loss from continuing operations was $2.4 million, or $(0.24) per share.
License and service revenues were $0.4 million.
Total operating expenses decreased by approximately 80.4% to $2.9 million.
The company is transitioning to a royalty-based business.
TherapeuticsMD
TherapeuticsMD
Forward Guidance
TherapeuticsMD is focused on its transformation into a royalty-based business, phasing out historical business operations, reducing costs, and conserving cash.